Depantol drug in the treatment of atrophic colpitis in women in perimenopausal period

Authors

DOI:

https://doi.org/10.18370/2309-4117.2015.26.82-84

Keywords:

atrophic colpitis, perimenopause, depantol

Abstract

In the treatment of aging atrophic vaginitis is widely used hormone replacement therapy. However, from 30% to 67% of women in the menopausal and perimenopausal period not using hormone replacement therapy.

The action of non-hormonal drugs used in the treatment of atrophic vaginitis, should be aimed at maintaining the level of lactobacillus and improve the regenerative capacity of the vaginal epithelium. Such properties have a drug depantol. This drug has not only the antibacterial activity but also stimulates the regeneration of the mucous membranes, normalizes cell metabolism, accelerates mitosis, increases the strength of collagen fibers.

A study to assess the efficacy of the depantol in atrophic colpitis in perimenopausal women was performed.

There were observed 52 patients with a diagnosis atrophic colpitis. All women were perimenopausal age surveyed ranged from 44 to 52 years old. Depantol prescribed 1 suppository 2 times a day for 20 days. The treatment was repeated after 2 weeks: twice in the same regime for 10 days. The efficacy of the therapy was evaluated according colpocytologic, microbiological research and determines the pH level.

Dryness of the vagina after treatment was observed in 19.2% of women, whereas before the treatment – in 84.6%. Dyspareunia after treatment observed rarely (5.2%), and its frequency prior to depantol use was 69.2%. Contact spotting after treatment were also absent. Majority of patients had reducing the amount of vaginal discharge. The index of maturity vaginal epithelium after therapy rose to 75–80 points in comparison with the 65–70 points before treatment.

Thus, the study showed that the drug depantol in perimenopausal women with atrophic colpitis provides a positive effect and significant antiseptic regenerative activity on vaginal epithelium, which allows recommending its wider use in clinical practice.

Author Biography

О. В. Кравченко, Bukovinian State Medical University

Obstetrics, Gynecology and Perinatology Department

References

Balan, V.E. Urogenital disorders in menopause (clinic, diagnostics, hormone replacement therapy). Thesis for the MD degree. Moscow (1998): 305 p.

Esefidze, J.T. “Clinic, diagnostics and therapy of the postmenopausal atrophic vaginitis.” Russian Medical Journal, 9 (Vol. 9) (2001): 370–373.

Zaporozhan, V.M., Yermolenko, T.O., Lavrynenko, G.L. “Complex treatment of atrophic vaginitis in women post menopause.” Reproductive Women Health, 1(17) (2004): 3–5.

Smetnik, V.P., Tumilovich, L.G. Non-operative gynecology. Guidelines for doctors. 3rd ed., rev. and add. Moscow. “MIA” (2003): 560 p.

Alsina, C.J. “The role of estrogen in urogynaecology high-dose therapy.” Maturitas, 33(1996): 51–57.

Barlow, D.H., Samsioe, B., van Geelen, I.M. “A study of European women experience of the problems of urogenital aging and its management.” Maturitas, 27(3) (1997): 239–247.

Samsioe, B. “Urogenital aging – a hidden problem.“ Am J Obstet Gynecol, 5 (Vol. 178) (1998): 245–249.

Published

2015-12-28

Issue

Section

Management of menopause

Most read articles by the same author(s)

1 2 > >>